Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.

MLA

Omole, Tosin, et al. “Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of MRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.” Vaccines, vol. 13, no. 2, Feb. 2025, p. 192. EBSCOhost, https://doi.org/10.3390/vaccines13020192.

APA

Omole, T., Pelayo, E., Weinberg, A. S., Chalkias, S., Endale, Z., Tamms, G., Sterling, T. M., Good, L., Shekar, T., Johnson, M., Banniettis, N., Buchwald, U. K., & Esteves-Jaramillo, A. (2025). Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines, 13(2), 192. https://doi.org/10.3390/vaccines13020192

Chicago

Omole, Tosin, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias, Zelalem Endale, Gretchen Tamms, Tina M. Sterling, et al. 2025. “Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of MRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.” Vaccines 13 (2): 192. doi:10.3390/vaccines13020192.